We take a look at the drugs that have been studied as treatments for confirmed prion diseases in humans – either in clinical trials, or on a compassionate, case-by-case basis – and look at what the future might hold for the treatment of prion diseases.
Take a look at the skip-and-resurgence of Japanese encephalitis, and the possible reasons behind this pattern, in our latest opinion piece.
Is Zika congenital syndrome, which affected thousands of babies born in Brazil during epidemics, associated with an increased host genetic susceptibility? And could Zika be a strong oncolytic agent against aggressive brain tumors? Find out in this opinion piece.
Cerebral malaria is the most severe neurological complication of Plasmodium falciparum infection. Here, the authors discuss how NRG-1 could attenuate brain injury and mortality.
Globally, shigella is reported to be the third largest cause of diarrheal mortality in the under-fives. We take a look at some of the vaccines that have made it to clinical development and some of the challenges still facing this diarrheal disease.
Take a look at how portable, long-read nanopore sequencing can be applied to the study of hepatitis B virus.
Recent technological advancements have allowed organoids to become a viable research tool for a wide range of development and disease models. Here, we look at some of the research that’s been done in infectious diseases and delve into what the future of organoids might look like.
Glenn Tillotson tells us about the interesting and rewarding opportunities young scientists could have in the pharmaceutical industry, highlighting how his own perceptions have changed over time.
Rabies elimination is achievable and cost-effective, but decades of research have failed to translate into multi-national efforts in the worst-affected areas. So why is the ancient rabies virus still terrorizing the lives of so many people across the globe?
Infectious diseases and population mobility are intimately linked from the perspectives of clinical practice to global health policy. Mobility bridges significant epidemiological differences in the classical determinants of health for all diseases. The new reality is that “surveillance, detection and response” activities in infectious diseases clinical care and public health are the responsibility all members of society.